Market research
CGIX Cancer Genetics, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 2.72
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US13739U2033
- Market cap
- 49M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 2.72
About
About Cancer Genetics, Inc
Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CGIX discussion.
5 years, 4 months ago
Cancer Genetics, Inc is currently in a long term uptrend where the price is trading 18.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Cancer Genetics, Inc's total revenue sank by 30.6% to $1M since the same quarter in the previous year.
Its net income has increased by 98.7% to $-4K since the same quarter in the previous year.
Finally, its free cash flow grew by 56.3% to $-1M since the same quarter in the previous year.
Based on the above factors, Cancer Genetics, Inc gets an overall score of 4/5.